Diethylenetriaminepentaacetic acid (DTPA) is a useful chelating agent for radionuclides such as 68 Ga, 99m Tc and 111 In, which are applicable to nuclear medicine imaging. In this study, we established a facile synthetic protocol for the production of mono-DTPA-conjugated peptide probes.
Introduction
Recent progress in molecular imaging methodologies such as positron emission tomography (PET), single-photon emission computed tomography (SPECT) and optical imaging technologies has significantly improved the early detection and diagnosis of malignant tumors. To visualize the specific molecular events involved in the physiological and/or pathological processes, a number of peptide-based imaging probes have been developed for overexpressed receptors of peptide hormones and extracellular matrix proteins. 1 These probes are usually designed by a combination of three components: a target-specific vector peptide, an imaging part such as a radionuclide or fluorophore, and a linker to covalently or noncovalently conjugate the peptide with the imaging moiety. The addition of a functional moiety onto small-sized bioactive peptides may be highly susceptible to interaction with receptors or counterpart molecules. Consequently, there have been many reagents of choice for appropriate protein/peptide modifications. In addition, to determine the best labeling position from structure-function relationship studies, versatile synthetic approaches toward various types of labeled peptide are desired.
Polyamino polycarboxylate ligands efficiently coordinate metal radioisotopes to aid the radiolabeling of bioactive peptides. Among the chelating ligands, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) 1a has been most widely utilized, since a variety of metal radioisotopes for both diagnostic and therapeutic purposes form complexes with high affinity and kinetic stability (Fig. 1) . 2 DOTA-modification of bioactive peptides is facilitated by commercially available reagents such as DOTA-NHS 1b and DOTA-maleimide 1c to provide the expected peptides in a single step. 3, 4 Alternatively, tris(tert-butyl)-DOTA 2a with a free carboxyl group is employed for the modification of an amino group of protected peptides bound to solid-supports. 5 Lysine or phenylalanine derivatives 2b,c possessing a tert-butyl-protected DOTA moiety are also useful components for the peptide sequence assembly. 6 tert-Butyl protecting groups in these reagents are easily removed during the final side-chain deprotection process of peptide synthesis.
In contrast to these DOTA derivatives, there has been limited work exploring the application of the diethylenetriaminepentaacetic acid (DTPA) chelating group 3a, although DTPA represents a promising alternative, especially for 68 Ga, 99m Tc and 111 In (Fig. 1) 7 The DTPA group also works as a more favorable functional group than DOTA to facilitate the biological or biodistribution properties of several probes. 8 For the preparation of DTPA-conjugated imaging probes, several conjugation reagents have been developed. The most familiar cyclic diethylenetriaminepentaacetic dianhydride 4 is a bifunctional chelating agent, which can conjugate with peptide hormones and antibodies. 9 Using this reagent, concomitant formations of a bis-conjugated product 10 and intra-and intermolecular cross-linked products 11 were unavoidable. Monoreactive DTPA derivatives have also been developed for the preparation of DTPA-peptide conjugates without the unfavorable by-product formations. 12, 13 For example, we reported the synthesis and application of 3,6,9,9-tetrakis[(tert-butoxycarbonyl)methyl]-3,6,9-triazanonanoic acid 3b (mDTPA), 14 in which the four carboxylates were protected with tert-butyl ester. However, a longer process from the commercially available reagents is required for the synthesis of these DTPA-conjugation reagents (Scheme 1a).
Accordingly, to establish a facile and efficient synthetic method for DTPA-peptide conjugates,
we have investigated the site-specific and on-resin construction of a DTPA moiety. Herein, we describe the short-step synthesis of a DTPA precursor using the o-nitrobenzenesulfonyl (Ns)
protecting group and the solid-phase synthesis of DTPA-peptide conjugates. The design and synthesis of DTPA-peptide conjugates that potentially target the somatostatin receptor and chemokine receptor CXCR4 are also presented. The synthetic scheme for the production of mDTPA reagent 10, as described in our previous study, is presented in Scheme 1A. We hypothesized that two remedies could significantly improve the overall synthetic process of DTPA-peptide conjugates. First, the use of an Ns group in place of the trifluoroacetyl group was expected to serve as a temporary protecting group and an auxiliary . 20 These suggest that this on-resin modification procedure is widely applicable to any chelating reagents with nucleophilic functional groups such as DTPA and DOTA precursors.
Site-specific DTPA-conjugation of bioactive peptides: synthesis of CXCR4 receptor probes.
It has been reported that a high level of CXCR4 expression in tumors is associated with malignant and metastatic properties. 21 Intrinsic SDF-1 release from the potential distal metastatic sites mediates organ-specific metastasis of CXCR4-expressing cells from the primary lesions. Since CXCR4-expressing cancer stem cells are related to the metastatic spread in orthotopic primary tumors, 22 it is of considerable importance to develop potent CXCR4-imaging probes to detect potential cancer stem cells within malignant tumors, as exemplified by the diagnosis of bladder cancer by a fluorescent CXCR4 probe.
23,24
Previously, we reported a DTPA-conjugated CXCR4 antagonist, DTPA-Ac-TZ14011 26a, 25 which was designed from a horseshoe crab-derived anti-HIV peptide T140. This peptide has β-sheet-like structures maintained by a disulfide bond, around which the pharmacophore residues for bioactivity are located. 26 For the site-specific conjugation at D-Lys 8 in the type II' β-turn region of T140 with a single DTPA group in the solution-phase, a secondary lysine (Lys 7 ) was substituted with arginine, which cannot be acylated by standard reagents. 25 Although a DTPA group was successfully ligated with maintenance of highly potent CXCR4 antagonistic activity in this case, 25 the accompanying substitutions needed for specific modification of other peptides may possibly lead to a decrease in the bioactivity. Therefore, we planned the facile site-specific DTPA conjugation on a solid-support for production of CXCR4 imaging probes without substitution of the secondary Lys 7 residue. To distinguish D-Lys 8 to be labeled in peptides 26, the highly acid-labile 4-methyltrityl (Mtt) group was exploited for temporary protection of the ε-amino group during solid-phase peptide synthesis. 27 For the other Lys residues such as Lys In-DTPA-labeled peptides 27a-c coincided with our previous report on the unlabeled peptides. 28 The novel potent In-DTPA-labeled CXCR4 antagonist 27c could be a promising imaging probe for CXCR4-expressing malignant cancer cells. 
Conclusions
In this study, we have established a novel synthetic method for the production of DTPA-peptide conjugates. The process includes facile solid-phase synthesis of a DTPA framework using a novel precursor substrate and site-specific conjugation using a highly acid-labile protecting group. Using a temporary Ns protecting group, the DTPA precursor 8 was obtained through two purification steps from commercially available diethylenetriamine. In addition, the on-resin incorporation of a bromoacetyl group into the specific free amino group followed by the addition of the nucleophilic DTPA precursors provided the expected DTPA-peptide conjugates with high purity. Taking To diethylenetriamine 5 (0.540 mL, 5.00 mmol) in dehydrated EtOH (5 mL 
Bis(tert-butyl) 3,6-bis[(tert-butoxycarbonyl)methyl]-3,6,9-triazaundecanedioate (8).
To a solution of compound 14a (0.216 g, 0.29 mmol) in DMF (0.726 mL), LiOH (0.128 g, 2.90 mmol) and mercaptoacetic acid (0.101 mL, 1.45 mmol) were added below 0 °C. After stirring for 2 h at room temperature, the mixture was concentrated under reduced pressure, and the residue was dissolved in CHCl 3 . The whole reaction mixture was washed with saturated NaHCO 3 , and was dried 
Standard procedure for solid-phase peptide synthesis.
Protected peptide-resins were manually constructed by Fmoc-based solid-phase peptide synthesis.
t-Bu ester for Asp and Glu; 2,2,4,6,7-pentamethyldihydrobenzofurane-5-sulfonyl (Pbf) for Arg;
t-Bu for Thr and Tyr; Boc for Lys and Trp; Trt for Cys were employed for side-chain protection.
Fmoc-amino acids were coupled using three equivalents of reagents [Fmoc-amino acid, 1,3-diisopropylcarbodiimide (DIC), and HOBt·H 2 O] to the free amino group in DMF for 1.5 h. Kyoto, Japan) and the purity was calculated as >95% by HPLC on a Cosmosil 5C18-ARII analytical column (Nacalai Tesque, 4.6 × 250 mm, flow rate 1mL/min) at 220 nm absorbance.
Preparation of DTPA-and DOTA-conjugated octreotides (19a,b).
According to the procedure reported previously, 18 
Preparation of DTPA-conjugated CXCR4 antagonists (26a-c).
Protected peptide resins were manually constructed according to the standard procedure using The DTPA group was incorporated using the identical procedure employed for the synthesis of the octreotide derivative 19a. 
Evaluation of [

